PharmacoEconomics

Acknowledgement

Comment on “The economics of follow-on drug research and development: Trends in entry rates and the timing of development”

Aidan Hollis

The economics of follow-on drug research and development: Trends in entry rates and the timing of development — The authors’ reply

Joseph A. DiMasi, Cherie Paquette

No room for kinkiness in a public healthcare system

Jack Dowie

Cost-effectiveness acceptability curves and a reluctance to lose

Johan L. Severens, Daniëlle E. M. Brunenberg, Elisabeth A. L. Fenwick, Bernie O’Brien, Manuela A. Joore

Willingness to pay for inhaled insulin

Hamid Sadri, Linda D. MacKeigan, Lawrence A. Leiter, Thomas R. Einarson

Estimating mean total costs in the presence of censoring

Tracey A. Young

A willingness-to-pay assessment of parents’ preference for shorter duration treatment of acute otitis media in children

Delphine Gueylard Chenevier, Jacques LeLorier

Pramipexole and levodopa in early parkinson’s disease

Katia Noyes, Andrew W. Dick, Robert G. Holloway

Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer’s disease

Colin Green, Joanna Picot, Emma Loveman, Andrea Takeda, Jo Kirby, Andrew Clegg

Rizatriptan

Paul L. McCormack, Rachel H. Foster